Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active and selective inhibitor of monoamine oxidase B (MAO-B) (IC50 = 1.33 nM) which can across the blood-brain barrier (BBB). Monoamine Oxidase B inhibitor 2 shows antioxidant and anti-neuroinflammatory activities which can be used in the study of Parkinson’s disease [1].

In cellular experiments, Monoamine Oxidase B inhibitor 2 (compound 8f; 0.5-10.0 μM) could significantly decrease the production of NO and TNF-α in LPS-stimulated BV-2 cells [1].

In in vivo acute and subacute MPTP-induced mice model of Parkinson’s disease, Monoamine Oxidase B inhibitor 2 (compound 8f; 6.3-39.5 mg/kg; oral administration) could significantly improve most behavioral disorders, restore the dopamine content and decrease the MDA content in the mice striatum [1].